Healthcare

Capital Raise Prioritizes Pipeline Continuity

New Endocrine Data Strengthens Development Case

Strategic Partnership in Ophthalmology Devices and Group Purchasing Organizations (GPOs)Iridex Corporation, a provider of laser-based medical systems for ophthalmology, has entered into a partnership with EyeProGPO, a U.S.-focused group purchasing organization serving more than 1,800 ophthalmology practices, ambulatory surgery centers, and hospitals. The agreement …

AtaiBeckley Inc. has reported Phase 2a clinical data for BPL-003, an intranasal psychedelic-based therapy targeting treatment-resistant depression (TRD), highlighting both rapid onset and sustained efficacy. The findings arrive as investor and industry attention toward next-generation mental health treatments continues to expand, particularly in segments …

FDA Orphan Drug Designation Expands Scope in Pediatric Brain Cancer TreatmentPlus Therapeutics has secured U.S. FDA Orphan Drug Designation for REYOBIQ, its investigational radiotherapeutic targeting pediatric malignant gliomas. Notably, the designation extends beyond the company’s initial request to include pediatric ependymoma, broadening the potential …

iBio IBIO-600 Phase 1 Trial Marks Transition to Clinical-Stage Biotech

UroGen Pharma Expands Clinical Engagement in LG-UTUC Treatment LandscapeUroGen Pharma Ltd. has introduced its “LG-UTUC Luminaries” initiative, a clinician- and institution-focused program aimed at advancing care standards for low-grade upper tract urothelial cancer (LG-UTUC). The initiative underscores the company’s broader strategy of embedding itself …